
GNFTF
Healthcare · Biotechnology · $472.5M market cap
$9.430.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 12, 2021 | After the close | -0.86 | 0.11 | +113.1% |
| Mar 31, 2021 | Time not confirmed | 0.00 | 0.11 | — |
| Nov 16, 2020 | Before the open | 0.00 | -0.76 | — |
| Sep 30, 2020 | After the close | -0.94 | -0.73 | +22.6% |
| May 18, 2020 | After the close | -0.67 | -0.76 | -14.0% |
| Jan 13, 2020 | Before the open | 0.00 | -0.75 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.18 | — |
| Sep 9, 2019 | After the close | — | -1.64 | — |
| Apr 30, 2019 | After the close | -0.65 | -0.93 | -43.5% |
| Feb 5, 2019 | Before the open | 0.00 | -0.92 | — |
| Oct 22, 2018 | After the close | 0.00 | -0.79 | — |
| Sep 24, 2018 | Before the open | 0.00 | -0.80 | — |
| Apr 27, 2018 | Before the open | 0.00 | -0.69 | — |
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial…
| Mar 13, 2018 |
| Before the open |
| 0.00 |
| -0.72 |
| — |